Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025)
4 hours ago
- #Acinetobacter
- #Sulbactam-durlobactam
- #Antimicrobial resistance
- Study evaluates the in vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains from non-respiratory and non-bloodstream infections.
- 285 isolates were collected from 17 U.S. states (2023-2025), primarily from skin/wound (58.6%) and urinary tract (31.6%) infections.
- Carbapenem resistance was observed in ~70% of isolates, more common in skin/wound cultures.
- Sulbactam-durlobactam showed high activity (96.9% susceptible; MIC90 4 mg/L), outperforming sulbactam alone (37.9% susceptible; MIC90 32 mg/L).
- Cefiderocol demonstrated >90% and >80% susceptibility at CLSI and FDA breakpoints, respectively.
- Minocycline susceptibility was 69.1%, while tigecycline and eravacycline showed MICs50/90 of 1/4 and 0.5/1 mg/L, respectively.
- Results align with previous studies on respiratory and bloodstream isolates, confirming sulbactam-durlobactam's broad efficacy.
- Findings highlight the importance of monitoring resistance patterns to guide treatment decisions for A. baumannii infections.